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Aim: To develop a prognostic molecular genetic model for assessing the risk of development of benign and malignant tumors of female 
reproductive organs (FRO) in patients from cancer-affected families. Patients and Methods: The work presents the data on a compre-
hensive clinical examination of 210 women (90 patients with FRO cancer with aggregation of tumor pathology in families, 65 patients 
with benign pathology of FRO from cancer-affected families, 55 women — control group of healthy women without family history 
of cancer). Clinical genealogical analysis, morphological examination of tumors and molecular genetic studies of genomic DNA from 
peripheral blood and tumors were carried out. Results: It was established that in the families of patients with benign and malignant 
pathology of FRO, malignant tumors associated with Lynch II syndrome are observed. Based on the analysis of detected ESR-1, 
CYP 2D6*4 and mutations in BRCA1/2 genes in cancer patients and in patients with benign pathology, molecular genetic models 
have been developed to assess the individual risk of development of benign and malignant tumors of FRO. It has been established 
that these molecular genetic models and combinations of gene mutations and gene polymorphisms (SNP) by the intergene interac-
tion that was analyzed, were found to be reliable in assessing the risk of benign and malignant pathology of the mammary gland and 
ovary. Conclusions: The model, which included the polymorphic variants of the T397C(ESR1)/CYP 2D6*4 genes was of the best 
predictive accuracy for the evaluation of the risk of benign tumors of the FRO (71.68%) and the highest reliability (p < 0.001). 
At the same time, all identified models of intergene interaction in the development of malignant pathology of FRO were reliable, 
prognostically significant with high reproduction and almost identical accuracy (65.00–68.23%). The obtained results indicate 
a high informativeness of such molecular genetic indices as the polymorphism of ESR1 and CYP 2D6*4 genes and mutations 
in BRCA1/2 genes to assess the risk of benign or malignant tumors of FRO in families of patients with family history of cancer.
Key Words: breast cancer, ovarian cancer, pedigree, family cancer syndrome, mutations in BRCA1/2 genes, gene polymorphisms 
of ESR1, CYP 2D6*4, molecular genetic models of individual cancer risk.
Among t�e current problems of clinical oncology 
�screening� prevention� early diagnosis� personalized 
treatment�� one of t�e topical issues — t�e individual 
risk of malignant neoplasms — is of particular inter-
est� alt�oug� for most of t�em� including cancer of t�e 
female reproductive organs �FRO�� risk factors are 
mostly already defined [���].
�eanw�ile� breast cancer �BC� and ovarian can-
cer �OC� still represent t�e most urgent medical and 
social problems. T�is is caused by t�e �ig� rates 
of cancer incidence in women in Ukraine and in many 
economically developed countries. Presently t�ere 
are developed modern concepts about t�e molecu-
lar genetic nature of malignant growt� and t�e value 
of �ereditary factors in t�e susceptibility for t�e de-
velopment of BC and OC [���]. At t�e present time� 
complex development of t�eoretical issues of genetics 
and molecular bio logy of tumors under t�e conditions 
of family �istory of cancer� �ereditary forms of BC� 
OC� Lync� type I�II syndromes and ot�er oncogenetic 
syndromes is becoming increasingly relevant [�].
T�ere are already accumulated data on a family 
aggregation of cancer of common genesis in several 
generations �cancer of t�e ovary or mammary gland� 
or cancer of various genesis �OC and BC� uterine and 
colon cancer� and ot�ers�� sync�ronicity or meta-
c�ronicity of tumors� manifestation of t�e tumor 
process in t�e young age. It �as been establis�ed 
t�at �ig�-penetrant germinal mutations in t�e tumor 
suppressor genes BRCA1 and BRCA2 are associated 
wit� �ig� risk of �ereditary forms of cancer� w�ereas 
in normal state t�ese genes are involved in repairing 
DNA damage and preservation of genetic stabil-
ity of cells [�� ��]; also� t�e polymorp�ism of ot�er 
genes could play a role in FRO cancer [��� ��]. T�e 
susceptibility for t�e development of BC and OC� 
�ormone dependent tumors� is strongly dependent 
on t�e gene polymorp�ism of ESR� receptor� w�ic� 
is involved in t�e �ormonal metabolism in normal 
cells and in t�e �ormonal pat�ogenesis of a number 
of malignant tumors [�3� ��]. We can not exclude t�e 
role of ot�er genes� including t�e gene CYP 2D6. Al-
lele variant of t�is gene� CYP 2D6*4� contributes to t�e 
transformation of tamoxifen in t�e intermediate active 
metabolite endoxifen� w�ic� determines t�e effec-
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tiveness of �ormonal treatment of BC patients [��]. 
T�erefore� from t�e point of improving t�e modern 
strategy of preclinical early diagnosis of cancer and 
t�e introduction of new screening programs for BC and 
OC� priority is given to determining t�e personalized 
risk of possible malignant growt� in women� depending 
on t�e family �istory of cancer and genetic c�anges 
in somatic or germinal cells [�� ��� ��]. T�is researc� 
direction is in t�e focus of t�e provisions of t�e NSGC 
�National Society of Genetic Counselors� and a series 
of studies in w�ic� conducting personalized genetic 
testing of women� taking into account t�e frequency 
of tumor pat�ology in t�e family� is t�e most urgent task 
for t�e development of individual genetic screening 
programs and early diagnosis of FRO cancer and as-
sessment of t�e risk of its possible development in t�e 
descendants of cancer patients [��� ��]. T�erefore� 
t�e determination of a predisposition to t�e develop-
ment of BC or OC is an important modern problem 
of oncogenetics� w�ic� requires furt�er researc� 
on family cancer �istory and genetic testing to assess 
t�e individual risk of developing cancer in members 
of families wit� a burden on cancer �istory. T�e risk 
of re-occurrence of cancer in a family can be deter-
mined by t�e use of already developed models based 
on t�e mat�ematical calculation of risk factors for 
t�e occurrence of BC or OC t�at are used in onco-
logy — Gail�odel �multivariate regression analysis 
of anamnesis data�� Claus�odel �segregation analysis 
of pedigree data� Couc��odel tested for mutations 
in t�e BRCA1 gene� and several ot�ers [�����].
In t�e work� we present models of intergene inter-
actions in t�e development of benign and malignant 
pat�ology in people wit� cancer-affected families 
based on t�e analysis of t�e combination of genetic 
c�anges in t�e genomic DNA of perip�eral blood and 
tumor cells in patients wit� BC and OC.
T�e aim of t�e work was to develop and test a prog-
nostic genetic model for assessing t�e risk of develop-
ing benign and malignant tumors of FRO in patients 
wit� cancer-affected families t�roug� a compre�ensive 
analysis of clinical genealogy and molecular genetic data 
on t�e combination of polymorp�ic variants of estrogen 
receptor gene ESR1� allelic variant of t�e CYP 2D6 gene� 
mutation of tumor suppressor gene BRCA1/2 in patients 
wit� BC and OC.
PATIENTS AND METHODS
In t�e study� t�e clinical data on ��� women from 
t�e C�erkasy region �age� nationality� complaints� data 
of objective status after examination by an oncogyne-
cologist and an oncology surgeon� results of mam-
mograp�ic examination� ultrasound of t�e pelvic 
organs and mammary glands� results of �istological 
examination of tumors of t�e mammary gland and 
ovaries� scraps of t�e uterine mucosa�� t�e data 
of t�e developed questionnaires for medical genetic 
counseling� pedigree� perip�eral blood of patients wit� 
benign pat�ology and malignant pat�ology of FRO wit� 
a family �istory of cancer and women from t�e control 
group wit�out complicated family oncoanamnesis� 
�ave been analyzed.
T�e study involved �� patients wit� benign pa-
t�ology of FRO �mammary gland� uterus� ovaries�� 
�� patients wit� cancer �BC� OC� from cancer-affected 
families� and �� practically �ealt�y women wit�out 
cancer cases in pedigrees. All women surveyed were 
Ukrainians.
Among t�e total number of patients �n = ���� 
���%�� t�e quantities of patients wit� benign pat�o-
logy �n = ��� 3�.�%�� BC �n = ��� ��.�%� and OC 
�n = ��� ��.�%� �in total� �� ���.�%� patients wit� 
cancer�� and �ealt�y women from t�e control group 
�n = ��� ��.�%� were close enoug� �Table ��. T�e 
age of patients wit� benign pat�ology� cancer of t�e 
FRO from cancer-affected families� and �ealt�y 
women from t�e control group fluctuated in t�e 
similar range — from �� to �� years �Table ��. T�e 
average age and median values for �� years did not 
�ave a significant difference in t�e groups of women 
surveyed �p > �.���.
T�e analysis of t�e reproductive-menstrual status 
of t�e examined women wit� benign pat�ology� pa-
tients wit� FRO cancer� and women from t�e control 
group is presented in Table 3.
Table 1. Distribution and characterization of FRO tumors in the examined 
patients (n = 155) with family history of cancer
Malignant  
pathology
Examined  
patients  
(n = 90), n (%)
Benign FRO pathology
Examined  
patients*  
(n = 65), n (%)
OC
46 (51.1)
Leiomyoma of the ute-
rus, uterine body ade-
nomyosis
19 (29.2)
BC 44 (48.9) Ovarian cyst 18 (27.7)
Fibroadenoma, cyst 
of the mammary gland 11 (16.9)
*A combination of dif-
ferent forms of benign 
FRO pathology
17 (26.2)
Total number 
of examined 
probands  
(n = 155)
Table 2. Distribution of probands (patients with benign pathology 
and malignant tumors of FRO from cancer-affected families and healthy 
women without cases of cancer of the pedigree — control group) 
by average and median age
Examined  
patients
Age, years
21–30 31–40 41–50 51–60 61–70 > 70
Patients with 
benign FRO 
pathology  
(n = 65/100%)
Median age
Average age
19/29.2%
29.2
26.2
15/23.1%
38.0
36.1
18/27.7%
48.0
45.1
8/12.3%
55.0
55.8
5/7.7%
62.0
63.4
−
Patients with 
FRO cancer  
(n = 90/100%)
Median age
Average age
5/5.6
29.0
28.6
18/20.0
33.0
36.5
31/34.4
41.0
46.5
23/25.6
53.0
54.7
9/10.0
65.0
64.0
4/4.4
73.0
72.0
Healthy wo-
men (control)
(n = 55/100%)
Median age
Average age
9/16.4%
29.0
27.7
27/49.0%
39.0
35.6
8/14.5%
48.0
46.6
9/16.4%
52.0
56.0
1/1.8%
−
1/1.8%
−
In total, 
210 patients
33 60 57 40 15 5
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Table 3. Distribution of cancer cases in families of probands with benign 
and malignant pathology of FRO (including tumors of probands)
Malignant tumors  
in families of probands
Number of cancer 
cases in pedigree 
in benign FRO  
pathology, n/%
Number of cancer  
cases in pedigree  
in malignant FRO  
pathology, n/%
Cancer of the uterus body 37/18.4 68/21.2
OC 38/18.9 58/18.1
BC 44/21.9 74/23.0
Colon cancer 72/35.8 101/31.5
Gastric cancer 10/5.0 20/6.2
Total 201/100 321/100
In 3�.�% of cancer patients� t�ere were previ-
ous surgical treatments of benign processes in t�e 
mammary gland and ovaries� w�ereas in t�e control 
group t�ere was no surgical interventions related 
to FRO. Similar tendency was observed in t�e group 
wit� benign pat�ology of FRO. Tumors in patients 
wit� benign pat�ology were significantly more of-
ten diagnosed during gynecological examination 
���.�%� t�an in cancer patients ���.�%�� in w�ic� 
t�e tumors were more often �in ��.�% of cases� 
found personally �in t�e case of t�e malignant 
pat�ology of t�e mammary gland�. T�e �ig�est 
number of benign and malignant neoplasms was 
diagnosed by t�e oncologist� oncogynecologist 
or oncology surgeon ���.� and ��.�%� respec-
tively�.
In all patients� t�e results of clinical� labora-
tory� instrumental researc� were analyzed� as well 
as clinical and genealogical data using a specially 
designed questionnaire� w�ic� was filled wit� pro-
band independently� and t�en t�e results were 
analyzed and supplemented by consultation wit� 
a gynecologist-oncologist during a personal conver-
sation wit� a proband and w�en reviewing medical 
documentation. after its compre�ensive examina-
tion in accordance wit� t�e Ukrainian standards. 
During t�e conversation wit� t�e patients� we �ave 
establis�ed t�e number of relatives �wit� and wit�out 
cancer pat�ology� and t�eir degree of relations�ip 
to proband �proband — patients wit� benign or ma-
lignant tumors of t�e FRO and �ealt�y women of t�e 
control group�.
During t�e conversation wit� proband� t�e fol-
lowing data were documented: t�e number of rela-
tives of t�e I�III degree of kins�ip wit� cancer� and 
t�eir exact diagnosis ascertained� if possible� using 
medical records� t�e relation of cancer patient relatives 
to proband. Clinical and genealogical analysis and 
pedigree analysis were performed according to t�e 
Amsterdam criteria II �t�ree or more relatives wit� 
Lync�-associated tumors — colorectal cancer� BC� 
cancer of uterus� ovary� gastric� and ot�ers� wit� one 
cancer patient �aving to �ave t�e I degree of kins�ip 
wit� ot�er relatives� and malignant tumors — at least 
in two generations�. In t�e examined �ealt�y women 
�control group�� t�ere were no cancer �istory in rela-
tives in t�e t�ree generations. All patients wit� benign 
and malignant FRO tumors� w�ic� underwent clinical 
and genealogical examination� received medical as-
sistance� including surgical� complex or combined 
treatment in accordance wit� its standards adopted 
in Ukraine� in C�erkasy Regional Oncology Dispensary 
�C�erkasy� Ukraine�. All probandes provided informed 
written consent to t�e use of t�e data and biologic 
materials in scientific researc�.
T�e analysis of clinical-genealogical data in pedi-
grees of patients wit� benign pat�ology and cancer �as 
revealed a wide range of tumor pat�ologies� among 
w�ic� predominated uterine cancer� OC� BC and 
colorectal cancer. T�e frequency of BC in benign/
malignant pat�ology in proband was ��.�/�3.�%� 
uterine cancer — ��.�/��.�%� OC — ��.�/��.�%� t�at 
is� t�e frequency of tumors of t�e �ormone-dependent 
organs was quite large and amounted to ��.�/��.3%� 
respectively. T�e data on cancer-affected relatives 
of probands wit� benign and malignant pat�ology 
of FRO are presented in Table 3.
According to t�e results of clinical and genea-
logical analysis of pedigrees� �� patients wit� benign 
pat�ology of FRO �aged �3��� years� in families wit� 
cancer �istory in ��� relatives of t�e I and II degree 
�Lync� II syndrome�� proband relatives on t�e ma-
ternal line were more likely to suffer from cancer 
��3/��.�%� t�an on parental line ���/��.�%�. In t�e 
analysis of pedigrees of �� patients wit� malignant 
tumors of FRO �from �� to �� years old�� an increase 
in t�e number of cancer cases in relatives on t�e 
maternal line compared wit� t�e parental line was 
noted bot� in patients wit� benign pat�ology of FRO 
����/��.�% and ��/��.�%� respectively�� and wit� 
malignant tumors ����/��.�% and 3�/��.�%� re-
spectively�. Also� �� women from t�e control group 
wit�out t�e presence of cancer �istory in pedigree 
were examined �Table ��.
Table 4. Frequency of malignant tumors in patients with cancer of rela-
tives of probands with benign FRO pathology
Data on oncogenetic counseling 
and clinical genealogical analysis  
of pedigrees
Benign 
(n = 65), 
201 cancer  
patients  
of probands 
in pedigree, 
n (%)
Malignant 
(n = 90), 
321 cancer  
patients  
of probands 
in pedigree, 
n (%)
I degree of kinship  
(2 relatives)
Maternal line 74 (36.8) 124 (37.6)
Paternal line 19 (9.5) 15 (4.7)
ІІ degree of kinship  
(2 relatives)
Maternal line 68 (33.8) 138 (43.9)
Paternal line 19 (9.5) 14 (4.5)
І–ІІ degree of kinship 
(3 or more relatives of pa-
tients with cancer, up to 6)
Maternal line 15 (7.5) 20 (6.2)
Paternal line
6 (2.9) 10 (3.1)
T�e stage of t�e tumor process in cancer patients 
was evaluated according to t�e FIGO classification. 
Clinical diagnosis was verified by morp�ological ex-
amination of surgically removed tumors. T�e surgical 
material of t�e patients was subjected to classical 
�istological analysis: staining of �istological sec-
tions wit� �ematoxylin and eosin and examination 
of slides using microscope “Axiostarplus” �“Carl-
Zeiss”� at magnification of �������. Histological 
peculiarities of malignant tumors and distribution 
of patients wit� OC and BC by t�e stages are pre-
sented in Table �.
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Table 5. Morphological and clinical characteristics of patients with 
BC and OC
Distribution  
of malignant tumors 
by morphology
Serous  
cancer
Adenocarci-
noma Ductal cancer
OC (n = 46/100%) 32/69.6% 14/30.4% −
BC (n = 44/100%) 13/29.5% 12/27.3% 19/43.2%
In total (n = 90/100%) 45/50% 26/28.9% 19/21.1%
Distribution 
of malignant 
tumors of FRO 
by stages
OC (46/100%) BC (44/100%)
І ІІ ІІІ ІV І ІІ ІІІ ІV
10 3 26 7 15 29 − −
21.7% 6.5% 56.6% 15.2% 34.1% 65.9% − −
As it is s�own in t�e Table �� malignant tumors 
of serous type were found more often in bot� OC 
���.�%� and BC ���.�%�� t�e most commonly of �ig� 
differentiation grade in bot� cases �G� ���.�%��. 
In stages among patients wit� malignant tumors of t�e 
OBR� T�e patients wit� OC were more often diagnosed 
wit� stage III of t�e disease ���.�%�� and wit� BC — 
in stage II ���.�%�.
�olecular genetic studies of perip�eral blood 
were carried out as follows: DNA extraction from 
perip�eral blood leukocytes� amplification of t�e 
studied DNA fragments� electrop�oretic distribution 
of amplification fragments� or analysis of restriction 
fragments in an agarose gel. Firstly� t�e total or total 
genomic DNA was collected from perip�eral blood 
leukocytes from ��� µl blood. For t�is purpose� 
a standard commercial kit wit� sorbent was used� 
t�e principle of w�ic� is t�at after t�e previous lysis 
of blood cells� released DNA is fixed on t�e sorbent. 
T�is facilitates t�e process of isolation and reduces 
its loss during furt�er purification. After fixing onto 
t�e sorbent� DNA was was�ed wit� special solu-
tions to obtain purified DNA wit� minimal impurities. 
Secondly� t�e number of copies of t�e studied gene 
fragments was increased in order to allow furt�er 
identification of t�e deletion variant or single-nucle-
otide replacement. Polymerase c�ain reaction �PCR� 
was used to multiply t�e number of copies of t�e 
fragment of t�e DNA under study. W�en conduct-
ing PCR� t�e synt�esis of complementary c�ains 
of t�e investigated DNA fragment in artificial condi-
tions is ac�ieved� w�ic� is ac�ieved due to optimal 
temperature conditions and due to t�e optimal ratio 
of reagents in t�e test tube.
�ultiplex PCR �amplification� was used to study 
t�ree mutations in BRCA1 �����delAG� �3��insC� 
and BRCA2 �����delT� genes in DNA samples 
from perip�eral blood. T�e resulting amplicons 
�ad different molecular weig�ts� so t�ey can 
be separated by t�e met�od of �orizontal agarose 
gel electrop�oresis. After standart PCR of DNA 
fragment of ESR1 gene �A-3��G� T-3��C� and 
CYP 2D6*4 gene �G����A� was performed a restric-
tion analysis of PCR products� and t�e fragments 
were analyzed also by comparison of restriction 
fragments in �.�% agarose gel by �orizontal elec-
trop�oresis.
For molecular genetic studies to detect ���delAG 
and �3��insC mutations  in BRCA1 gene� ����delT 
mutation in BRCA1 gene� mutations ����delTu 
in BRCA2 gene and polymorp�ic variants of ESR 
gene �A-3��G� T-3��C� and CYP 2D6*4  gene 
�G����A�� genomic DNA was also isolated from t�e 
�istological sections of t�e paraffin blocks of t�e op-
eration material from �� patients wit� BC ��3/��%� 
and OC ��3/��%�. T�e material was delivered in mi-
crotubes to t�e laboratory of t�e State Institution 
“Reference Center for �olecular Diagnostics of t�e 
�inistry of Healt� of Ukraine”. For deparaffinization 
to paraffin sections� ��� µl of ���% xylene were 
added� vortexed for �� s� and incubated at room 
temperature not less t�an � �. T�e samples were 
centrifuged for � min at ������ g� supernatant was 
removed. T�e deparaffinization procedure was re-
peated again in t�e same way. To remove t�e xylene 
residues after de-paraffinization� t�e samples were 
was�ed in four steps according to t�e standard 
procedure [�3].
To detect mutations in t�e genes and t�e pres-
ence of 185delAG and �3��insC mutations in t�e 
BRCA1 gene� mutations in 6174delTu in BRCA2 gene� 
and polymorp�isms in ESR1 �A-3��G� T-3��C� and 
CYP 2D6*4 �G����A� genes� t�e study was performed 
on perip�eral blood samples of patients wit� fam-
ily �istory of cancer� namely: �� patients wit� BC 
�n = ��� and OC �n = �3�� and �� women wit� benign 
neoplasms of FRO wit� family �istory of cancer. 
Also� molecular genetic studies of perip�eral blood 
were conducted for t�e presence of t�e same poly-
morp�isms in �� practically �ealt�y women from t�e 
control group� wit�out known �ereditary risk factors 
for malignant pat�ology.
T�e perip�eral blood was collected in sterile tubes 
of t�e system “�onovet” in volume of �.� ml wit� 
et�ylenediaminetetraacetic acid �EDTA� manufac-
tured by t�e company “Sarstedt”. Sterile tubes 
wit� t�e obtained material were stored at −�� °C 
�no more t�an � mont�� in freezers until t�ey were 
transported to t�e molecular genetic laboratory 
of t�e Reference Center for �olecular Diagnostics 
of t�e �inistry of Healt� of Ukraine. Transportation 
of t� samples was carried out in frozen state in cold 
containers. For t�e extraction of DNA from perip�eral 
blood� t�e commercial kit “DNA-Sorb-B” was used 
according to t�e instructions of t�e manufacturer. 
Determination of t�e polymorp�ism of t�e genes 
studied was carried out using a PCR wit� T�ermo-
Scientific reagents� using a standard protocol [��] 
and specific primers.
Statistical processing was performed using pro-
grams �SExcel ���� and Statistica ��. To analyze 
t�e differences in t�e obtained numerical indices� 
t�e met�ods of variation statistics were used� t�e 
genotype frequencies — Pearson’s criterion χ�� 
if a sample size of less t�an �� — t�e Yates correc-
tion was used� and odds ratio �OR� was calculated 
wit� a confidence interval ���% confidence inter-
val — CI�.
To assess t�e role of intergene interaction in t�e 
development of benign and malignant pat�ologies 
in t�e examined women and t�e creation of genetic 
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risk models� t�e �ultifactor Dimensionality Reduc-
tion ��DR �.�� using t�e appropriate software: �DR 
�version �.�.� �ttp://www.epistasis.org/mdr.�tml� was 
used [��].
Using t�is met�od� we conducted a statistical 
evaluation of t�e reproducibility of t�e tested mod-
els. In t�e �DR program� multiloci genotypes are 
summarized in groups of increased and reduced risk 
of developing t�e disease. Wit� t�e �elp of multiple 
cross-recounting of t�e initial data entered� t�e 
optimal model of intergene interactions is selected� 
w�ic� allows wit� t�e �ig�est accuracy and� accord-
ingly� wit� t�e slig�test error� to predict t�e presence 
or absence of a predisposition to t�e develop-
ment of benign or malignant tumors �pat�ological 
states�. T�e mat�ematical basis of t�is program 
is a nonparametric cluster analysis� w�ic� serves 
as an alternative to logistic regression to identify and 
describe t�e nonlinear type of interaction between 
discrete genetic markers. In t�e process of model-
ing� we used �ig�ly conservative configuration set-
tings for model searc�� w�ic� allowed us to uniquely 
differentiate t�e presence/absence of statistically 
significant effects: t�e number of attributes �at-
tribute count range� — from � to n �w�ere n — t�e 
number of genes in t�e model�; reproducibility 
of t�e model �cross-validation count� — ��. We �ave 
calculated χ²� t�e relative risk index OR at ��% CI� 
t�e differences were considered to be significant 
at p < �.��.
RESULTS AND DISCUSSION
T�e analysis of t�e frequencies of t�e genotypes 
of t�e investigated genes was carried out differen-
tially — depending on t�e number of patients wit� 
benign or malignant pat�ology in t�e families. T�e 
control group involved practically �ealt�y women from 
cancer-uncomplicated pedigree.
T�e results of t�e statistical analysis �Table �� 
of t�e genotype frequencies for polymorp�ic vari-
ants of ESR1 gene �T397C� s�owed t�at in patients 
wit� benign pat�ology of FRO� a significant increase 
in t�e frequency of t�e 397СС genotype was found 
in t�e case of aggregation of malignant pat�ology 
in pedigrees compared wit� t�e frequency of t�is 
genotype in women of t�e comparison group �wit�-
out cancer-burdened anamnesis �OR = �.��� ��% 
CI �.�����.��� p = �.�����. In t�e presence of 397TC 
genotype of ESR1 gene� t�e risk of developing 
benign pat�ology is significantly lower �OR = �.��� 
��% CI �.����.3�� p = �.����. For 397TT genotype� 
a protective effect �a decrease in t�e risk of devel-
oping pat�ology� was establis�ed �OR = �.��� ��% 
CI �.����.3�� p = �.����. Among t�e patients wit� 
benign tumors� t�e frequency of genotypes 397CC + 
397CT �OR = �.��� ��% CI �.����3.��� p = �.���� 
prevalents wit� �ig� reliability� t�at is� t�e presence 
of t�is polymorp�ic variant in t�e �omo- or �et-
erozygous state increases t�e risk of development 
of benign tumors by �.� times.
Table 6. Distribution of polymorphic variants of ESR1 (T-397C, A-351G) 
and CYP 2D6*4 (G1846A) genes in patients with benign FRO pathology 
and healthy women (control group)
Genotypes
Benign  
pathology
(n = 65)
Control 
group
(n = 55)
Results of statistical analysis
n % n % χ² p OR 95% CI
ESR1 (T397C) gene
ТТ 14 21.54 34 61.82 18.5 0.001 0.17 0.08–0.38
TC 36 55.38 18 32.73 5.3 0.021 2.55 1.21–5.38
СС 15 23.08 3 5.45 5.94 0.015 5.20 1.42–19.06
TC + CC 51 78.46 21 38.18 8.50 0.001 5.90 2.64–13.17
ESR1 (A351G) gene
AA 23 35.38 37 67.27 10.88 0.001 0.27 0.12–0.57
AG 32 49.23 18 32.73 2.69 0.101 1.99 0.95–4.19
GG 10 15.38 0 0.00 7.33 0.007 – –
AG + GG 42 64.62 18 32.73 10.88 0.001 3.75 1.76–8.02
CYP 2D6*4 (G1846A) gene
GG 42 64.62 45 81.82 4.42 0.035 0.41 0.17–0.95
GA 17 26.15 10 18.18 0.68 0.411 1.59 0.66–3.84
AA 6 9.23 0 0.00 3.58 0.059 – –
GA + AA 23 35.38 10 18.18 4.53 0.032 2.34 1.05–5.14
According to our data� t�e genotypes AA and 
GG of ESR1 gene �ave a protective effect� and for 
AG genotype of t�is gene t�e data were insignificant 
�p > �.���.
T�e risk of development of benign pat�ology 
in t�e presence of an unfavorable polymorp�ic vari-
ant 1846GA or 1846AA of CYP 2D6*4 gene in t�e 
�omo- or �eterozygous state increases by �.3� times 
�p = �.�3�� ��% CI �.����.���� w�ereas in t�e pres-
ence of t�e 1846GG genotype of t�is gene� t�e risk 
of developing t�e disease is reduced �OR = �.��� 
��% CI �.����.��� p = �.�3��. T�us� t�ere is a differ-
ent risk of benign pat�ology in women wit� cancer-
affected families burdened wit� malignant pat�ology: 
a significant increase by �.3� times �genotype GA + 
AA of CYP 2D6*4 gene�� 3.�� times �AG + GG genotype 
of ESR1 gene� and �.��-�.�� times �genotypes TC, 
CC, TC + CC of ESR1 gene�.
Distribution of polymorp�ic variants of t�ese genes 
in cancer patients wit� family �istory of cancer is pre-
sented in Table �.
In patients wit� FRO cancer� t�ere was registered 
a typical increase in t�e frequency of 397Ts and 
397SS genotypes of ESR1 (T397C� gene� as com-
pared to controls �OR = �.��� ��% CI �.����.��� p = 
�.�3�� and OR = �.��� ��% CI �.�����.��� p = �.���� 
respectively�. T�e genotype 397TT �ad a protective 
effect regarding t�e development of oncopat�ology 
�OR = �.��� ��% CI �.����.��� p = �.����. As can 
be seen from Table �� in t�e presence of a polymor-
p�ic variant of 397CC or 397CT in �omo- or �eterozy-
gous state� t�e risk of developing cancer is increased 
by �-fold.
In patients wit� FRO cancer t�ere was found 
just a tendency to increased frequency of 351GG 
genotype in ESR1 gene �p > �.���. Significant differ-
ences were found for 351AG genotype of ESR1 gene 
�OR = �.��� ��% CI �.3���.��� p = �.����� w�ile for 
351AA genotype — a protective effect �OR = ���� ��% 
CI �.����.��� p = �.����. In t�ese patients a significant 
increase in t�e frequency of 1846GA and 1846AA geno-
types of CYP 2D6*4 gene was observed� on t�e basis 
of w�ic� it can be stated t�at t�e risk of developing 
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cancer in t�e presence of an unfavorable polymorp�ic 
variant in �omo- or �eterozygous state increases 
by �.�� times.
Table 7. Distribution of polymorphic variants of ESR1 (A-351G, T-397C), 
CYP 2D6*4 (G1846A) and BRCA1/2 genes in cancer patients with OC with 
a burden of the oncological pathology in the families and in the women 
from the control group
Genotypes
Malignant 
pathology
(n = 90)
Control 
group
(n = 55)
Results of statistical analysis
n % n % χ² p OR 95% CI
ESR1 (T397C) gene
ТТ 23 25.56 34 61.82 17.33 0.001 0.21 0.10–0.44
TC 47 52.22 18 32.73 4.49 0.034 2.25 1.12–4.52
СС 20 22.22 3 5.45 5.99 0.014 4.95 1.40–17.55
TC + CC 67 74.44 21 38.18 17.33 0.001 4.72 2.29–9.70
ESR1 (A351G) gene
AA 30 33.33 37 67.27 14.48 0.001 0.24 0.12–0.50
AG 52 57.78 18 32.73 7.61 0.006 2.81 1.39–5.67
GG 8 8.89 0 0.00 3.61 0.057 – –
AG + GG 60 66.67 18 32.73 14.48 0.001 4.11 2.01–8.39
CYP 2D6*4 (G1846A) gene
GG 60 66.67 45 81.82 3.2 0.074 0.44 0.20–1.00
GA 28 31.11 10 18.18 2.32 0.128 2.03 0.90–4.60
AA 2 2.22 1 0.00 0.14 0.704 – –
GA + AA 30 33.33 10 18.18 3.92 0.047 2.25 1.00–5.07
BRCA1 (5382insC) gene
NN 80 88.89 55 100.00 4.95 0.026 – –NM 10 11.11 0 0.00 – – –
MM 0 0.00 0 0.00 – – – –
BRCA2 (6174delТ) gene
NN 86 95.56 55 100.00 1.13 0.288 – –NM 4 4.44 0 0.00 – – –
MM 0 0.00 0 0.00 – – – –
In general� in cancer patients compared wit� 
patients wit�out family �istory of cancer� 5382insC 
mutation in t�e BRCA1 gene in t�e �eterozygous 
state �χ² = �.��� p = �.���� was detected at sig-
nificant rate; in � cases 6174delT mutations in t�e 
BRCA2 gene in t�e �eterozygous state were de-
tected �see Table ��.
To evaluate t�e complex contribution of t�e 
genetic component to t�e development of cancer 
pat�ology� we conducted an analysis of all possible 
combinations of polymorp�ic variants of t�e inves-
tigated genes in t�e groups of examined patients 
�Table ��.
Subsequently� using bioinformatics met�od 
of �DR �.�� we evaluated t�e role of t�e combination 
of genes and intergene interactions to form a model 
of intergene interaction in t�e development of benign 
tumor pat�ology in t�e examined women �Table ��.
Table 9. Established models of intergene interaction in the development 
of benign pathology using the MDR 2.0 program in comprehensive search 
mode
Number  
of genes in model
Combinations of genes 
in prognostic model
Reproduci-
bility of the 
model
Accuracy 
of the  
model, %
1* T397C 10/10 70.14
2** T397C/CYP 2D6*4 10/10 71.68
3* T397C/A351G/CYP 2D6*4 10/10 67.20
4* insC/T397C/A351G/
CYP 2D6*4 10/10 69.79
Notes: *The best model (p ≤ 0,01) among the n-gene models is determined.
**The best model (p ≤ 0,001) among the n-gene models is determined.
T�e best prognostic model wit� �ig� accuracy 
���.��%� to predict benign pat�ology in women wit� 
family �istory of cancer is a model wit� two genes 
ESR1 (T397C) and CYP 2D6*4 (G1846A) w�ic� can 
be used for t�e study of gene polymorp�ism. Using 
grap�ic imaging� we determined t�e contribution 
of eac� polymorp�ism to t�e risk of developing a pa-
t�ology �Fig. �� ��. T�e �ig� entropy index ��3.��%� 
was determined for t�e estrogen receptor gene 
ESR1 (T397C)� w�ic�� according to t�e image� �as 
a negative relations�ip wit� ot�er genes �blue and 
green�� i.e. �as a predominantly isolated effect on t�e 
increase of t�e risk of t�e disease. Based on t�e analy-
sis of all four indeces� we can conclude on t�e leading 
role of t�e T397C polymorp�ism in ESR1 gene among 
all t�e analyzed genes.
In cancer patients and women of t�e control group� 
an assessment of genotypes combinations of t�e in-
vestigated genes was performed �Table ���.
Table 10. Combinations of genotypes of the investigated genes 
ESR1 (T397C/A351G), CYP 2D6*4 (G1846A) and BRCA1 (5382insC), 
BRCA2 (6174delT) associated with an increased risk of malignant 
pathology
Combinations 
of genotypes
Malignant 
pathology
(n = 90)
Control 
group
(n = 55)
Results  
of statistical analysis
n % n % χ² OR p 95% CI
ESR1 (T397C/A351G)
TT/AA 21 23.33 32 58.18 12.63 0.26 0.001 0.12–0.53
TC/AG 38 42.22 13 23.64 4.39 2.36 0.036 1.12–5.00
CC/GG 8 12.31 0 0.00 5.17 – 0.047 –
ESR1 (T397C)/CYP 2D6*4 (G1846A)
TT/GG 17 18.89 25 45.45 10.45 0.28 0.001 0.13–0.59
TC/GA 16 17.78 1 1.82 6.93 11.68 0.008 1.50–80.74
ESR1 (A351G)/CYP 2D6*4 (G1846A)
AA/GG 19 21.11 27 49.09 12.33 0.28 0.001 0.13–0.58
AG/GA 14 15.56 0 0 9.46 – 0.013 –
T397C/A351G/G1846A
TT/AA/GG 15 16.66 23 41.82 9.9 0.28 0.002 0.13–0.60
TC/AG/GA 11 12.22 0 0 7.27 – 0.018 –
BRCA2 (6174delT)/T397C/A351G/CYP 2D6*4 (G1846A)
NM/TC/AG/GA 1 1.11 0 0.00 0.06 – 0.803 –
NM/TC/AA/GG 1 1.11 0 0.00 0.06 – 0.803 –
NM/CC/AG/GG 2 2.22 0 0.00 0.14 – 0.704 –
BRCA1 (5382insC)/T397C/A351G/CYP 2D6*4 (G1846A)
NM/TT/AA/GA 1 1.11 0 0.00 0.06 – 0.803 –
NM/TC/AA/GA 1 1.11 0 0.00 0.06 – 0.803 –
NM/TC/AG/GG 3 3.33 0 0.00 0.59 – 0.443 –
NM/TC/AG/GA 4 4.44 0 0.00 1.13 – 0.288 –
As can be seen from Table �� we �ave identified 
protective combination of genotypes and combina-
Table 8. Combinations of genotypes of the studied  
ESR1 (T397C/A351G), CYP 2D6*4 (G1846A) and BRCA1 (5382insC) 
genes associated with an increased risk of benign FRO pathology
Combination 
of genotypes
Benign  
pathology
(n = 65)
Control  
group  
(n = 55)
Results of statistical analysis
n % n % χ² OR p 95% CI
ESR1 (T397C/A351G)
TT/AA 13 20.97 32 58.18 16.94 0.18 0.001 0.08–0.40
TC/AG 27 41.54 13 23.64 4.29 2.30 0.038 1.04–5.08
CC/GG 10 15.38 0 0.00 7.33 – 0.007 –
ESR1 (T397C)/CYP 2D6*4 (G1846A)
TT/GG 8 12.31 25 45.45 14.80 0.17 0.001 0.07–0.42
CC/GA 6 9.23 0 0.00 5.34 – 0.021 –
ESR1 (A351G)/CYP 2D6*4 (G1846A)
AA/GG 15 23.08 27 49.09 7.76 0.31 0.005 0.14–0.68
AG/GA 7 10.77 0 0.00 6.28 – 0.012 –
GG/GG 5 7.69 0 0.00 4.41 – 0.035 –
T397C/A351G/G1846A
TT/AA/GG 8 12.31 23 41.82 13.54 0.20 0.001 0.08–0.49
TT/AA/GA 3 4.61 9 16.36 4.08 0.22 0.049 0.06–0.86
TC/AG/GA 5 7.69 0 0.00 4.41 – 0.035 –
CC/GG/GG 5 7.69 0 0.00 4.41 – 0.035 –
BRCA1 (5382insC)/T397C/A351G/CYP 2D6*4
NM/CC/AG/GG 1 1.54 0 0.00 0.85 – 0.356 –
NM/CC/GG/GA 1 1.54 0 0.00 0.85 – 0.356 –
NM/CC/GG/GG 1 1.54 0 0.00 0.85 – 0.356 –
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tions of genotypes associated wit� an increased 
risk of FRO. Among t�e women from t�e control 
group� t�e combination of TT/AA, TT/GG, AA/GG, 
TT/AA/GG was significantly predominant compared 
to ESR1 and CYP 2D6*4 genes. T�e frequency of gen-
otypes TC/AG, TC/GA, AG/GA, TC/AG/GA of ESR1 and 
CYP 2D6*4 genes was �ig�er in t�e cancer patients 
group. In t�e control group CC/GG, AG/GA, TC/AG/
GA combinations were not find at all� t�erefore� t�e 
OR was not calculated for t�is group� but t�eir similar 
prevalence among patients points to t�eir importance 
in relation to increased risk of pat�ology.
�utat ions in  �ig�-penetrant  BRCA1  and 
BRCA2  genes �see Table �� were also found 
in combination wit� ot�er investigated genotypes 
of ESR1 �A351G, T397C� and CYP 2D6*4 (G1846A� 
genes. In � out of �� cases� we found a combination 
of BRCA1 (5382insC) wit� genotypes of t�e investi-
gated genes t�at increase t�e risk of oncological pa-
t�ology� and in � of t�e � cases� t�e BRCA2 genotype 
(6174delT) was associated wit� t�e genotype of t�e 
�ig� risk of oncological pat�ology� indicating a modi-
fying effect t�ese genotypes in t�e presence of �ig�-
penetrant mutations. A similar modifying effect was 
observed in patients wit� benign pat�ology in w�om 
BRCA1 (5382insC) genotype was combined wit� t�e 
risk genotypes of t�e investigated genes.
In t�e modeling of intergene interaction in cancer 
patients and in control group� t�e one-locus model 
t�at included t�e ESR1 gene �T397C� wit� an accuracy 
of ��.�3% wit� a reproducibility of ��% was found 
to be t�e best model for prediction �Table ���.
To predict malignant pat�ology� t�e study 
of ESR1 (T397C� gene polymorp�ism s�ould be con-
ducted� w�ic� �ad t�e �ig�est degree of entropy — 
��.��%� and an independent negative relation wit� 
ot�er genes �entropy — degree of uncertainty�.
T�us� as can be seen from t�e data presented� t�e 
patients and families wit� a family �istory of onco-
logical pat�ologies s�ould first undergo an analysis 
of ESR1 gene polymorp�ism �T397C� for treatment 
planning and an indication of preventive measures. 
If we analyze t�e data in general� we can conclude 
t�at in t�e era of personalized medicine and person-
alized oncology� in particular� t�e key direction is t�e 
identification of individual risk factors of t�e disease 
and conditions t�at may be associated wit� t�em and 
manifest in t�e early stages of tumor growt� [��� ��]. 
Suc� a provision dictates t�e development of ge-
netic programs for t�e prevention and early diagnosis 
of neoplasia� w�ic� will promote not only t�e discov-
ery of genetic and molecular genetic signs of tumor 
growt�� but also t�e ability to distribute tumors accord-
ing to t�e �eterogeneity of suc� c�anges. T�e latter 
is also important for targeted molecular t�erapy and 
Fig. 1. Grap�ical representation of t�e results of t�e analysis 
of interactions between t�e investigated genes in women wit� 
benign pat�ology
Note: green� blue — antagonistic interaction between t�e gene 
loci� brown color — t�e independent effect of individual loci on t�e 
risk of t�e disease. T�e lines between t�e genes on Fig. � s�ows 
t�e type and degree of interaction. T�e long lines in t�e dendro-
gram describe a weak link between t�e genes� s�ort lines — stron-
ger interaction� t�e color c�aracterises t�e type of interaction: 
blue — t�e independent effect� green — t�e en�ancing effect 
of t�e gene. On t�e apexes of t�e poly�edron is t�e informative 
value of eac� gene� on t�e edges — t�e informative value of t�e 
interaction of a pair of genes. Since t�e nature of t�e interaction 
of t�e investigated genes in t�e model �ad an independent effect� 
t�e interaction between t�e genes is negative.
Fig. 2. Grap�ical representation of t�e results of t�e analysis 
of interactions between t�e investigated genes in cancer patients
Note: green� blue colors — antagonistic interaction between t�e 
loci� ot�er marks — see Fig. �.
Table 11. Models of intergene interaction in the development 
of malignant pathology of FRO defined using the MDR 2.0 program 
in comprehensive search mode
The number 
of genes in the 
model
Combinations of genes 
in the prognostic model
Reproduc-
ibility of the 
model
Accuracy 
of the  
model, %
1* T397C 9/10 68.23
2* insC/T397C 8/10 66.11
3* T397C/A351G/CYP 2D6*4 7/10 65.56
4* insC/T397C/A351G/
CYP 2D6*4 7/10 65.00
Note: *The best model (p ≤ 0.05) among n-gene models is determined.
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t�e development of new approac�es to t�e prevention 
and treatment of FRO cancer [��� ��].
�olecular c�anges in non-malignant cells� includ-
ing mutations and polymorp�isms of genes� in t�e 
absence of breast or ovarian pat�ology in women 
from cancer-affected families� are reliable indicators 
of genetic instability of somatic or germ cells� w�ic� 
is of fundamental importance for t�e study of t�e 
tendency of an organism to develop tumors. A posi-
tive example of t�is trend in modern researc�� in par-
ticular early screening of OC� is a program PRO�ISE 
���� �Predicting Risk of Ovarian �alignancies� Im-
proved Screening and Early Detection�� w�ic� takes 
into account not only clinical data on t�e patients� but 
also t�e proteomic and genetic c�aracteristics of cells 
and �ig�-penetrant genes �BRCA1/2) and a number 
of ot�er genes �BRIP1, RAD51C and RAD51D� [��].
T�e importance of furt�er studying genetic c�ang-
es in cells is important for t�e genetic testing of women 
from families wit� �istory of cancer. According to t�e 
literature� genetic c�anges in tumor cells are predictive 
factors for t�e sensitivity to platinum preparations and 
are associated wit� tumor c�emoresistance as a re-
sult of mutations associated wit� tumor progression� 
as well as survival of patients wit� OC� BC� and fallopian 
tubes [���3�]. In our opinion� alt�oug� t�e mutations 
and single nucleotide polymorp�isms �SNPs� reliably 
reflect t�e molecular c�anges of t�e already developed 
tumors� knowledge of t�e individual c�aracteristics 
of tumor growt�� t�at is� its personal p�enotype� re-
quires knowledge of its morp�ological� proteomic and 
metabolic c�aracterization� w�ic� will make it possible 
to detail t�e c�anges in tumor cells in general and more 
correctly establis� t�e prognosis of t�e tumor process. 
In addition� t�e emergence of t�e possibility of deter-
mining t�e molecular c�anges in nonmalignant cells 
of patients wit� cancer-affected families improves 
t�e effectiveness of medico-genetic counseling via 
a compre�ensive examination of patients for t�e di-
agnosis of tumor growt� in t�e early stages or at t�e 
stage of its preclinical manifestations� followed by t�e 
appropriate preventive measures.
So� t�e clinical and genealogical analysis of pedi-
grees of patients wit� FRO cancer �as establis�ed 
accumulation of tumor pat�ology in t�e form of fam-
ily cancer syndrome and �ereditary forms of OC and 
BC. According to t�e results of molecular-genetic 
examination of patients wit� benign pat�ology and 
FRO cancer after an analysis of intergene interaction 
in groups of patients wit� benign and malignant pat�ol-
ogy of FRO and control group� it was establis�ed t�at 
t�e polymorp�ic variants of ESR1 gene �ad a major 
influence on t�e development of t�e pat�ology.
T�e best predictive accuracy for t�e evaluation 
of t�e risk of benign tumors of t�e FRO ���.��%� 
and t�e �ig�est significance �p < �.���� was t�e 
model� w�ic� included t�e polymorp�ic variants of t�e 
T397C(ESR1)/CYP 2D6*4 genes. At t�e same time� 
all establis�ed models of intergene interaction in t�e 
development of malignant pat�ology of FRO were reli-
able� prognostically significant wit� �ig� reproduction 
and almost identical accuracy ���.�����.�3%�.
T�e obtained results indicate a �ig� informative-
ness of suc� molecular genetic indices as t�e poly-
morp�ism of ESR1 and CYP 2D6*4 genes and muta-
tions in BRCA1/2 genes to assess t�e risk of benign 
or malignant tumors of FRO in families of patients wit� 
family �istory of cancer. T�is gives t�e rig�t to recom-
mend t�e described molecular genetic models for 
practical use in oncology to assess t�e risk of benign 
and malignant pat�ology in families in w�ic�� accord-
ing to genealogical data� aggregation of malignant 
tumors �as been identified.
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